Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
LABU vs PRHSX
Shared holdings
66
LABU covered by PRHSX
24.07%
PRHSX covered by LABU
24.07%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 50 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
LABU (April 30, 2026)
| Security | Weight | |
|---|---|---|
| DREYFUS GOVT CASH MGMT FUND | 7.43% | |
| US ULTRA BOND CBT Sep25 | 7.26% | |
| GOLDMAN FINL SQ TRSRY INST 506 | 6.27% | |
| GOLDMAN SACHS FIN GOV 465 INSTITUT | 1.71% | |
| APELLIS PHARMACEUTICALS INC | 1.44% | |
| REVOLUTION MEDICINES INC | 1.27% | |
| TRAVERE THERAPEUTICS INC | 1.25% | |
| ARROWHEAD PHARMACEUTICALS INC | 1.11% | |
| TWIST BIOSCIENCE CORP | 1.10% | |
| SUMMIT THERAPEUTICS INC | 1.09% | |
| ALKERMES PLC | 1.07% | |
| TG THERAPEUTICS INC | 1.06% | |
| MADRIGAL PHARMACEUTICALS INC | 1.06% | |
| BEAM THERAPEUTICS INC | 1.02% | |
| APOGEE THERAPEUTICS INC | 0.98% | |
| SCHOLAR ROCK HOLDING CORP | 0.95% | |
| PRAXIS PRECISION MEDICINES INC | 0.95% | |
| EXELIXIS INC | 0.94% | |
| MIRUM PHARMACEUTICALS INC | 0.93% | |
| UNITED THERAPEUTICS CORP DEL | 0.92% | |
| NATERA INC | 0.92% | |
| CELCUITY INC | 0.92% | |
| CRISPR Therapeutics A.G. Series A | 0.92% | |
| KRYSTAL BIOTECH INC | 0.91% | |
| PROTAGONIST THERAPEUTICS INC | 0.90% | |
| NEUROCRINE BIOSCIENCES INC | 0.89% | |
| INCYTE CORP | 0.89% | |
| CG ONCOLOGY INC | 0.89% | |
| CYTOKINETICS INC | 0.89% | |
| NUVALENT INC-A | 0.88% | |
| IONIS PHARMACEUTICALS INC | 0.88% | |
| BRIDGEBIO PHARMA INC | 0.88% | |
| VAXCYTE INC | 0.88% | |
| KYMERA THERAPEUTICS INC | 0.88% | |
| BIOGEN INC | 0.87% | |
| COGENT BIOSCIENCES INC | 0.87% | |
| PTC THERAPEUTICS INC | 0.87% | |
| INSMED INC | 0.86% | |
| ALNYLAM PHARMACEUTICALS INC | 0.85% | |
| ROIVANT SCIENCES | 0.85% | |
| HALOZYME THERAPEUTICS INC | 0.84% | |
| ARCUTIS BIOTHERAPEUTICS INC | 0.83% | |
| SPYRE THERAPEUTICS INC | 0.83% | |
| SOLENO THERAPEUTICS INC | 0.82% | |
| ABBVIE INC | 0.82% | |
| AMGEN INC | 0.81% | |
| REGENERON PHARMACEUTICALS INC | 0.80% | |
| ULTRAGENYX PHARMA INC | 0.80% | |
| ACADIA PHARMACEUTICALS INC | 0.80% | |
| RHYTHM PHARMACEUTICALS INC | 0.80% |
PRHSX (March 31, 2026)
| Security | Weight | |
|---|---|---|
| LILLY ELI and CO | 10.14% | |
| THERMO FISHER SCIENTIFIC INC | 4.07% | |
| INTUITIVE SURGICAL INC | 3.65% | |
| STRYKER CORP | 3.46% | |
| MERCK & CO | 3.44% | |
| ASTRAZENECA PLC | 3.17% | |
| UNITEDHEALTH GRP | 3.09% | |
| ARGENX SE SPONSORED ADR | 2.92% | |
| ABBVIE INC | 2.84% | |
| REGENERON PHARMACEUTICALS INC | 2.65% | |
| GILEAD SCIENCES INC | 2.60% | |
| JOHNSON&JOHNSON | 2.44% | |
| VERTEX PHARMACEUTICALS INC | 2.43% | |
| DANAHER CORP | 2.05% | |
| ALNYLAM PHARMACEUTICALS INC | 1.62% | |
| Ascendis Pharma A/S | 1.42% | |
| REVOLUTION MEDICINES INC | 1.36% | |
| UNITED THERAPEUTICS CORP DEL | 1.34% | |
| BEONE MEDICINE-H | 1.19% | |
| ROIVANT SCIENCES LTD | 1.13% | |
| PROTAGONIST THERAPEUTICS INC | 1.11% | |
| INSMED INC | 1.06% | |
| SUMMIT THERAPEUTICS INC | 1.04% | |
| NATERA INC | 1.03% | |
| TENET HEALTHCARE CORP | 1.01% | |
| BRIGHTSPRING HEALTH SERVICES INC | 0.98% | |
| AMGEN INC | 0.98% | |
| BOSTON SCIENTIFIC CORP | 0.92% | |
| HCA HEALTHCARE INC | 0.90% | |
| GUARDANT HEALTH INC | 0.90% | |
| CVS HEALTH CORP | 0.86% | |
| KYMERA THERAPEUTICS INC | 0.77% | |
| THE CIGNA GROUP | 0.74% | |
| CG ONCOLOGY INC | 0.69% | |
| CARDINAL HEALTH INC | 0.68% | |
| ELEVANCE HEALTH INC | 0.66% | |
| KRYSTAL BIOTECH INC | 0.65% | |
| SCHOLAR ROCK HOLDING CORP | 0.62% | |
| IONIS PHARMACEUTICALS INC | 0.61% | |
| BRIDGEBIO PHARMA INC | 0.59% | |
| CHUGAI PHARMA CO | 0.58% | |
| STRUCTURE THERAPEUTICS INC ADR | 0.56% | |
| PRAXIS PRECISION MEDICINES INC | 0.56% | |
| CELCUITY INC | 0.56% | |
| ROYALTY PHARMA PLC | 0.55% | |
| CENCORA INC | 0.52% | |
| CENTESSA PHARMACEUTICALS LTD ADR | 0.50% | |
| VERA THERAPEUTICS INC | 0.46% | |
| NUVALENT INC-A | 0.43% | |
| APOGEE THERAPEUTICS INC | 0.43% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.